1 report

  • Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers
  • Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares
  • Cancer
  • Europe
  • United States
  • Product Initiative
  • Kiadis Pharma N.V.